[
  {
    "question": "MS patient on fingolimod for couple of years developed weakness and slurred speech. VZV done it was positive his JCV before starting treatment was -ve. What to do next:",
    "option_a": "This is relapse, give methylprednisolone",
    "option_b": "repeat JCV & urgent MRI brain",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroimmunology",
    "explanation": "MS patients on immunomodulatory agents such as fingolimod are at risk not only for disease relapse but also for opportunistic infections or treatment-related complications. New neurological deficits in this context demand differentiation between an MS relapse, an infection (such as a viral reactivation), or even a rare drug complication like PML. Fingolimod functions by sequestering lymphocytes in lymph nodes, reducing their circulation. This immune modulation increases vulnerability to viral reactivation, including varicella zoster virus (VZV) and potentially John Cunningham virus (JCV), which is linked to PML. Although fingolimod has a lower risk for PML compared to natalizumab, seroconversion or reactivation can occur during long-term treatment. The patient\u2019s presentation with weakness and slurred speech raises concerns for several possibilities, including an MS relapse, VZV encephalopathy/vasculopathy, or the early stages of PML. The positive VZV test further suggests an infectious process. Rechecking the JCV status and performing an urgent MRI help distinguish among these conditions, as MRI can identify lesion patterns typical for PML or MS, and a change in JCV status would raise suspicion for PML. Key steps include: 1) Urgent brain MRI to assess lesion characteristics and distribution; 2) Repeating JCV serology to determine if seroconversion has occurred; 3) Possibly obtaining CSF analysis (including viral PCR panels and oligoclonal bands) to further evaluate the etiology of the neurological deficits. Differential diagnoses include MS relapse, PML, VZV encephalopathy, and other central nervous system infections. Management depends on the definitive diagnosis. If the symptoms were due to an MS relapse, high-dose IV methylprednisolone would be indicated. However, if imaging and repeat JCV testing point to PML or another infection (like VZV encephalopathy), corticosteroids may be contraindicated and fingolimod should be reconsidered. In such cases, antiviral treatment (for VZV) or cessation of the immunomodulatory agent might be warranted. Note that while pregnancy/lactation is not a factor in this case, in general adjustments in immunosuppressive therapy are needed if the patient were pregnant. Option A suggests treating this as an MS relapse with methylprednisolone, which would be inappropriate if an opportunistic infection or PML is present because steroids could worsen an infectious process. Option B, which directs the clinician to repeat JCV testing and obtain an urgent MRI, is the best approach to differentiate between an MS relapse and a serious complication such as PML or a VZV-related CNS infection. Options C and D are not provided and thus not analyzable. 1) Fingolimod increases the risk of opportunistic infections through immunosuppression. 2) New neurological symptoms in patients on immunomodulators warrant prompt imaging and laboratory re-evaluation. 3) Distinguishing an MS relapse from infection is critical, as treatment strategies differ markedly. Recent studies and guidelines underscore the need for thorough investigations when patients on agents like fingolimod develop new neurological signs. MRI remains the cornerstone of evaluation, and updated recommendations advise re-assessing viral serologies (including JCV) to exclude PML, especially in the context of new symptoms.",
    "exam_year": "2018",
    "exam_type": "Promotion"
  },
  {
    "question": "Case scenario about temporal arteritis:",
    "option_a": "ESR",
    "option_b": "prednisolone 60-80 mg / day",
    "option_c": "prednisolone 40-60 mg / day",
    "option_d": "is not provided.",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuroimmunology",
    "explanation": "Temporal arteritis, also known as giant cell arteritis, is a vasculitis affecting medium and large arteries, particularly in older adults. It presents with systemic and cranial symptoms, and swift intervention is crucial to prevent permanent visual loss. The condition involves granulomatous inflammation of the arterial wall leading to luminal narrowing and ischemia. Inflammatory cells, including multinucleated giant cells, contribute to vessel wall damage and can result in tissue ischemia, particularly in the optic nerve. Patients typically present with headache, jaw claudication, scalp tenderness, and visual disturbances. The elevation of inflammatory markers (ESR and CRP) is common. In cases without visual impairment, an oral corticosteroid regimen is typically initiated to quickly reduce inflammation. Evaluation includes laboratory tests (especially ESR and CRP) and confirmation with a temporal artery biopsy. Differential diagnoses include other causes of headache (e.g., migraine, tension headache) and other vasculitides like polymyalgia rheumatica, which often coexists with giant cell arteritis. The first-line treatment for temporal arteritis without immediate visual loss is high-dose oral corticosteroids. Current guidelines recommend initiating prednisolone at a dosage of 40-60 mg per day. In patients with visual symptoms or imminent threat to vision, doses may be escalated to 60-80 mg per day or an IV regimen (e.g., IV methylprednisolone) may be used. For pregnant or lactating women, the benefits of corticosteroids generally outweigh the risks, but careful monitoring and lowest effective dosing is recommended. Option A (ESR) refers to a diagnostic test rather than treatment. Option B (prednisolone 60-80 mg/day) is appropriate in cases with severe visual involvement or a high risk of vision loss. Option C (prednisolone 40-60 mg/day) is the standard first-line treatment in typical cases without impending visual loss, making it correct in the given scenario. Option D is not provided. 1) Early recognition and treatment of temporal arteritis are critical to prevent blindness. 2) A high index of suspicion is needed in patients over 50 with a new headache and elevated ESR. 3) Temporal artery biopsy, although the gold standard, may sometimes be deferred in emergent cases to start treatment promptly. Recent guidelines (including those from ACR and EULAR) continue to support the use of high-dose corticosteroids as immediate therapy in temporal arteritis. Emerging data also highlight the importance of tapering guidelines and monitoring for steroid-related adverse effects, with ongoing research into steroid-sparing agents.",
    "exam_year": "2018",
    "exam_type": "Promotion"
  },
  {
    "question": "Primary progressive MS McDonald 2017",
    "option_a": "39-man progressive symptoms over 2 months with periventricular hyperintense lesion",
    "option_b": "30-man progressive symptoms over one yr. ....",
    "option_c": "40-year-old with progressive ataxia over one year and T2 hyperintensity with no OCB.",
    "option_d": "39-year-old man with progressive symptoms over 12 months cortical hyperintense lesion and OCB.",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Neuroimmunology",
    "explanation": "Primary progressive multiple sclerosis (PPMS) is characterized by a gradual, steady progression of neurological disability from the onset, without distinct relapses or remissions. The diagnosis relies on clinical progression over time, supported by radiological and laboratory findings. In PPMS, there is chronic demyelination, axonal loss, and neurodegeneration primarily occurring from the onset. Inflammatory activity is less pronounced than in relapsing-remitting MS but is present, as evidenced by oligoclonal bands (OCBs) in the cerebrospinal fluid and characteristic MRI findings. Patients with PPMS typically present in mid-adulthood with a gradual deterioration in neurological function over at least a year. Common symptoms include motor deficits, spasticity, and cerebellar dysfunction. The presence of OCBs and characteristic lesions on MRI further support the diagnosis. Diagnosis according to the McDonald 2017 criteria for PPMS requires: (1) one year of disease progression, and (2) at least two of the following supportive criteria: evidence of dissemination in space (demonstrated by typical MRI lesions), a positive CSF (OCB), or spinal cord lesions. Differential diagnoses include other chronic progressive myelopathies such as vascular myelopathy, neurodegenerative disorders, or metabolic causes. Management of PPMS is challenging. While traditional disease-modifying therapies are more effective in RRMS, ocrelizumab is currently approved for PPMS and has shown modest benefits in slowing progression. Management remains largely symptomatic. In pregnant or lactating patients, careful risk\u2013benefit analysis is required as disease-modifying therapies may have contraindications; typically, treatment is deferred or adjusted during pregnancy. Option A describes a case with too short a duration (2 months), which does not satisfy the criterion of one year progression. Option B is incomplete and lacks key details. Option C describes a case that lacks OCB evidence, making it less definitive. Option D describes a patient with 12 months of progressive symptoms, a cortical hyperintense lesion on MRI, and positive OCB, which fulfills the McDonald 2017 requirements for PPMS, making it the best choice. 1) PPMS is diagnosed based on a continuous progression over at least one year. 2) The presence of MRI lesions and positive OCB increases diagnostic certainty. 3) PPMS tends to have fewer inflammatory relapses, making conventional relapse therapies less effective. The McDonald 2017 criteria remain the standard for MS diagnosis. Recent research supports the modest benefits of ocrelizumab in PPMS, marking a significant shift in therapeutic options for this traditionally hard-to-treat subtype.",
    "exam_year": "2018",
    "exam_type": "Promotion"
  },
  {
    "question": "Young lady known to have MS; she is pregnant asking about percentage of risk of her baby to have MS.",
    "option_a": "2 - 4 %",
    "option_b": "15-20%",
    "option_c": "30 - 40%",
    "option_d": "as general population",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Multiple sclerosis is a multifactorial autoimmune demyelinating disorder with both genetic and environmental components. While there is a familial predisposition, the absolute risk for offspring remains relatively low. Although certain genes (such as HLA-DRB1*15:01) are associated with an increased risk of MS, the disease is polygenic and influenced by environmental exposures. The modest increase in risk among children of affected individuals reflects this complex interplay. MS typically does not directly transmit in a simple Mendelian pattern. Children born to MS patients have an increased lifetime risk compared to the general population; however, the actual risk remains low in absolute terms. This question is epidemiological rather than diagnostic. The risk assessment is based on observational studies comparing the incidence of MS in the general population versus those with a family history. In the context of pregnancy, the management of MS focuses on balancing disease control with safety for the fetus. Most disease-modifying therapies are either discontinued or switched to agents with better safety profiles during pregnancy and lactation. Counseling regarding genetic risk is an important part of preconception planning. Option A (2-4%) accurately reflects the increased risk for offspring of an MS patient, which is modestly higher than the general population\u2019s baseline risk. Option B (15-20%) and Option C (30-40%) significantly overestimate the risk. Option D (as general population) underestimates the modest increase observed in epidemiological studies. 1) Children of MS patients have an approximately 2-4% risk of developing MS, which, while higher than the general population, remains relatively low in absolute terms. 2) MS does not follow a strict Mendelian inheritance pattern. 3) Pre-pregnancy counseling is essential for women with MS to discuss familial risk and management of disease-modifying therapies. Recent epidemiologic studies confirm that while there is an increased risk of MS in offspring of affected parents, the absolute risk remains around 2-4%. Current guidelines advocate for individualized counseling and management of MS in pregnancy, with careful consideration given to the continuation or modification of disease-modifying therapies during pregnancy and lactation.",
    "exam_year": "2018",
    "exam_type": "Promotion"
  },
  {
    "question": "Which of the following is counted as a red flag of MS?",
    "option_a": "Partial myelitis",
    "option_b": "Decrease facial sensation",
    "option_c": "Complete gaze palsy",
    "option_d": "Erectile dysfunction",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuroimmunology",
    "explanation": "Multiple sclerosis (MS) is an autoimmune, demyelinating disorder of the central nervous system which typically presents with discrete episodes (relapses) and partial neurological deficits that reflect lesions in characteristic regions (periventricular, juxtacortical, infratentorial, and spinal cord). A 'red flag' in the context of MS refers to atypical clinical findings that are not characteristic of the disease and warrant consideration of alternative diagnoses. MS lesions result from immune-mediated attack against myelin with resultant plaque formation. Typically, these lesions produce partial deficits (for example, internuclear ophthalmoplegia) rather than complete loss of function. A complete gaze palsy suggests a more extensive brainstem involvement than usually seen in MS and may indicate other pathologies (eg, stroke or brainstem encephalopathy). Clinically, MS patients classically manifest with partial, often transient, deficits that disseminate in time and space. In contrast, a complete gaze palsy \u2013 where the patient loses the ability to move the eyes in a particular direction \u2013 is uncommon and should alert the clinician to consider alternate pathologies affecting the brainstem. Approach involves detailed neurological examination and MRI imaging to evaluate lesion size, location and morphology. Red flags such as complete gaze palsy demand further workup to rule out acute brainstem ischemia, mass lesions, or other inflammatory processes. Differential diagnoses include stroke, brainstem neoplasms, and other central nervous system infections. Management of confirmed MS involves disease-modifying therapies (DMTs) such as interferon-beta, glatiramer acetate, ocrelizumab, and others. When atypical features (red flags) are present, the workup must be broadened. In pregnancy and lactation, many DMTs are contraindicated or require careful risk\u2010benefit assessment; for example, interferon-beta may be considered in certain circumstances while others like ocrelizumab are avoided due to potential fetal risks. Option A (Partial myelitis) is a common presentation in MS; Option B (Decrease facial sensation) can be seen as part of trigeminal involvement but is not a red flag; Option C (Complete gaze palsy) is atypical (red flag) for MS because MS usually causes partial ocular motor deficits; Option D (Erectile dysfunction) is a non-specific symptom that can occur in advanced MS but is not considered a red flag for diagnosis. 1. MS typically presents with partial deficits that are disseminated in time and space. 2. A complete gaze palsy is unusual in MS and suggests an alternative diagnosis. 3. Always re-evaluate atypical neurological findings to avoid misdiagnosis. Recent guidelines and studies emphasize the importance of recognizing red flag features in patients suspected of having MS, to prevent misdiagnosis and inappropriate treatment. Advanced MRI techniques help differentiate typical demyelinating lesions from those seen in other etiologies.",
    "exam_year": "2018",
    "exam_type": "Promotion"
  },
  {
    "question": "50 years old developed progressive symptoms started sensory left lower limb then progress involving bilateral lower limb increase with standing sensory level T10 MRI T2 hyperintense long lesion and conus with hypodense rim in T1. Most likely diagnosis?",
    "option_a": "NMO",
    "option_b": "spine Infarction",
    "option_c": "AVM spine",
    "option_d": "Dural venous fistula",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Neuroimmunology",
    "explanation": "Spinal dural arteriovenous fistula (DAVF) is a type of vascular malformation where an abnormal connection between a dural artery and a venous channel leads to venous hypertension and subsequent myelopathy. This condition typically affects older adults, particularly men. The abnormal arteriovenous shunting in a DAVF leads to chronic venous congestion. This congestion impairs normal spinal cord perfusion and results in progressive myelopathy. The MRI findings of a T2 hyperintense long lesion with a hypointense rim on T1, especially involving the conus medullaris, are highly suggestive of venous congestion secondary to a DAVF. Clinically, patients with spinal DAVFs classically present with slowly progressive motor and sensory deficits in the lower extremities. Symptoms may worsen with upright posture due to increased venous pressure. A sensory level (eg, at T10, as in the case described) corresponds to the level of venous congestion and cord involvement. The differential diagnosis for a longitudinally extensive myelopathy includes neuromyelitis optica (NMO), spinal cord infarction, and arteriovenous malformations. Spinal DAVF is differentiated by its insidious onset in older individuals, characteristic MRI findings including the rim sign on T1, and the worsening of symptoms with standing. Definitive diagnosis is typically made with spinal digital subtraction angiography (DSA). The first-line management of spinal DAVF is endovascular embolization, with surgical ligation reserved for cases where endovascular treatment fails or is not feasible. In a pregnant or lactating patient, interventional procedures require a multidisciplinary approach to minimize risks and exposure to radiation or contrast agents. Conservative management is generally not effective due to the progressive nature of the condition. Option A (NMO) is usually associated with optic neuritis and is more common in younger females. Option B (Spine infarction) typically has an acute onset rather than a progressive course. Option C (AVM spine) would show distinct flow voids and serpiginous vascular structures on MRI. Option D (Dural venous fistula) best fits the clinical picture of an older male, progressive myelopathy with characteristic MRI findings. 1. Spinal DAVF should be suspected in older patients with progressive lower extremity myelopathy that worsens on standing. 2. The presence of a T2 hyperintense longitudinal lesion with a T1 hypointense rim in the conus area is a key imaging clue. 3. Early diagnosis is critical to prevent irreversible spinal cord damage. Recent studies and guidelines underscore the need for prompt diagnosis of spinal DAVF, often through DSA, and early intervention via endovascular treatment to prevent long-term disability.",
    "exam_year": "2018",
    "exam_type": "Promotion"
  },
  {
    "question": "MS pathophysiology most common evidence with:",
    "option_a": "EBV",
    "option_b": "Vit B12",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Multiple sclerosis (MS) is an autoimmune demyelinating disorder of the central nervous system. Epidemiologic evidence has strongly linked Epstein\u2013Barr virus (EBV) infection to the development of MS. EBV infects B-cells and may trigger an aberrant immune response via mechanisms such as molecular mimicry. The body's immune response to EBV antigens might cross-react with myelin proteins, thereby contributing to the demyelination seen in MS. In contrast, vitamin B12 deficiency leads to subacute combined degeneration but is not implicated in MS pathogenesis. A history of symptomatic EBV infection (infectious mononucleosis) has been associated with a higher risk of developing MS later. Patients with MS often have evidence of past EBV infection indicated by seropositivity for anti-EBV antibodies. Diagnosis of MS is based on McDonald criteria which include clinical evaluation and MRI findings, while serological studies (such as EBV antibody titres) may provide supportive epidemiologic evidence. Vitamin B12 levels are measured when there is suspicion of metabolic demyelination, but they do not play a role in MS diagnosis. MS is managed with disease-modifying therapies (DMTs), acute relapse management (eg, corticosteroids), and symptomatic treatments. For patients who are pregnant or lactating, treatment selection must consider fetal and neonatal risks; interferon-beta, for instance, has been used cautiously while other agents like ocrelizumab are typically deferred until after pregnancy. Option A (EBV) is supported by a robust body of epidemiological and mechanistic evidence as being strongly associated with MS. Option B (Vit B12) relates to a deficiency state causing demyelination in subacute combined degeneration but is not a pathogenic evidence in MS. 1. Prior EBV infection is one of the most consistently observed risk factors for MS. 2. Nearly all patients with MS are seropositive for EBV. 3. Vitamin B12 deficiency can mimic demyelinating conditions but is not involved in MS pathogenesis. Recent large-scale and longitudinal studies have reinforced the link between EBV seropositivity and an increased risk of MS, driving further research into potential EBV-targeted preventive strategies.",
    "exam_year": "2018",
    "exam_type": "Promotion"
  },
  {
    "question": "Ocrelizumab mechanism of action:",
    "option_a": "CD20",
    "option_b": "Sphingo\u2026",
    "option_c": "CD52",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Ocrelizumab is a humanized monoclonal antibody used in the treatment of multiple sclerosis. Its mechanism of action involves targeting and depleting CD20-positive B cells, which are implicated in the autoimmune processes underlying MS. B cells play a key role in MS by producing pro-inflammatory cytokines, presenting antigens, and possibly producing antibodies that contribute to myelin destruction. By targeting CD20 on B cells, ocrelizumab reduces these pathogenic immune responses. Alternative targets like sphingosine-1-phosphate receptors (as with fingolimod) or CD52 (as with alemtuzumab) represent different therapeutic strategies. Ocrelizumab is used in both relapsing-remitting MS (RRMS) and primary progressive MS (PPMS). Clinical trials have demonstrated its efficacy in reducing relapse rates and slowing progression of disability. It is particularly noteworthy as one of the first approved treatments for PPMS. The use of ocrelizumab is based on the diagnosis of MS, established via clinical criteria (eg, McDonald criteria) and MRI findings. An understanding of its mechanism also helps differentiate it from other DMTs that target different molecules. First-line management of MS traditionally involves interferons or glatiramer acetate for RRMS, although ocrelizumab is now a major option, especially in cases with highly active disease or PPMS. In pregnancy and lactation, ocrelizumab is generally avoided due to potential risks to the fetus; women of childbearing age should practice effective contraception during treatment and for a period after the last infusion, as recommended in current guidelines. Option A (CD20) is correct since ocrelizumab specifically targets CD20 on B cells. Option B (Sphingo\u2026) likely refers to fingolimod's mechanism and Option C (CD52) is the target of alemtuzumab; therefore, A is the only correct answer. 1. Ocrelizumab is the first approved therapy for primary progressive MS and is highly effective in depleting CD20-positive B cells. 2. It revolutionized MS treatment by offering an option for patients with progressive forms of the disease. 3. Its use requires careful counseling regarding contraception due to potential fetal risks. Recent studies confirm that targeting CD20-positive B cells with ocrelizumab significantly reduces relapse rates and slows disability progression in MS. Ongoing research is focused on further delineating the role of B cells in MS and optimizing treatment regimens.",
    "exam_year": "2018",
    "exam_type": "Promotion"
  },
  {
    "question": "15-year-old girl present to emergency room with confusion and seizure. Her parents note that she has been more forgetful and irritable. Her behavior has also become bizarre. On the morning of the presentation, she had generalized tonic clonic seizure. IV acyclovir and phenytoin started. MRI of the brain and EEG are normal. After three days her clinical status does not improve. CSF PCR is negative for HSV, VZV, EBV, which of the following autoantibodies is most likely to be responsible for her presentation?",
    "option_a": "Hu antibody",
    "option_b": "NMDA receptor antibody",
    "option_c": "Voltage gated potassium channel",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroimmunology",
    "explanation": "Anti\u2013NMDA receptor encephalitis is an autoimmune disorder in which antibodies target NMDA receptors in the brain. It is most commonly seen in young females and can be paraneoplastic (often associated with an ovarian teratoma) or idiopathic. The typical presentation includes rapid-onset psychiatric symptoms, memory deficits, seizures, and altered mental status. The disease involves autoantibodies (primarily IgG against the NR1 subunit of the NMDA receptor) that lead to receptor internalization. This results in dysregulation of synaptic transmission without overt cell death early on. The underlying immune process leads to brain dysfunction manifesting as seizures, behavioral abnormalities, and movement disorders. It is an example of antibody-mediated encephalitis that may not initially show abnormalities on MRI or EEG. Patients typically present with a constellation of neuropsychiatric symptoms: confusion, memory loss, behavioral changes, and seizures. In a teenager with normal initial MRI and EEG, a lack of improvement with acyclovir along with negative CSF PCR panels for common viral encephalitides should prompt evaluation for autoimmune causes. The condition\u2019s association with ovarian teratoma in females also adds a paraneoplastic dimension that should be evaluated. The diagnosis is based on clinical presentation and confirmed with the detection of NMDA receptor antibodies in the CSF (and sometimes serum). Differential diagnoses include HSV encephalitis (ruled out by PCR), other autoimmune encephalitides, metabolic encephalopathies, and psychiatric disorders. A careful review of imaging, EEG, and CSF studies is essential to exclude alternative causes. First-line treatment involves immunotherapy (high-dose corticosteroids, IVIG, or plasmapheresis) along with early tumor screening and removal if a teratoma is detected. Second-line therapies include rituximab and cyclophosphamide. For pregnant or lactating patients, corticosteroids and IVIG are generally considered safer options, while the use of other immunosuppressants should be carefully weighed against potential fetal risks. Early diagnosis and treatment are critical for improved outcomes. Option A (Hu antibody) is associated with paraneoplastic encephalomyelitis mainly in older patients with small-cell lung cancer. Option B (NMDA receptor antibody) is correct for this age and clinical scenario. Option C (Voltage gated potassium channel antibody) is more typically linked to limbic encephalitis, which generally affects an older population and has a different clinical spectrum. Option D was not provided. \u2022 Anti\u2013NMDA receptor encephalitis often masquerades as a psychiatric disorder in young women. \u2022 Normal initial imaging does not exclude the diagnosis. \u2022 Early treatment with immunotherapy can substantially improve outcomes. Recent studies and updated guidelines emphasize early recognition and initiation of immunotherapy for anti\u2013NMDA receptor encephalitis. New research is also focusing on optimal immunosuppressive strategies and the role of tumor removal in paraneoplastic cases, with encouraging results from multicenter observational studies.",
    "exam_year": "2018",
    "exam_type": "Promotion"
  },
  {
    "question": "18-year-old women is referred to your office after branch retinal artery occlusion occurred in each eye several months apart. Her examination reveals moderate hearing loss in the right ear in addition to visual field cuts in each eye. A brain MRI reveals multiple small cortical strokes in the frontal lobes and left parietal lobe. What is the diagnosis?",
    "option_a": "Multiple sclerosis",
    "option_b": "ADEM",
    "option_c": "Susac syndrome",
    "option_d": "Conversion reaction.",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuroimmunology",
    "explanation": "Susac syndrome is a rare autoimmune microangiopathy that affects the small vessels of the brain, retina, and inner ear. Its classic clinical triad involves encephalopathy, branch retinal artery occlusions (BRAO), and sensorineural hearing loss. The condition is mediated by an immune process causing endotheliopathy of precapillary arterioles. This results in microinfarctions in the brain, retinal ischemia due to BRAO, and cochlear damage leading to hearing loss. Inflammation and subsequent vascular occlusion underpin the clinical manifestations. In this clinical scenario, the patient\u2019s history of sequential branch retinal artery occlusions, hearing loss, and evidence of multiple small cortical strokes on MRI strongly point toward Susac syndrome. These findings distinguish it from other demyelinating or inflammatory conditions. Diagnosis is supported by the clinical triad. Ancillary testing involves brain MRI (often showing small multifocal infarcts predominantly in the corpus callosum), fluorescein angiography to document BRAO, and audiometry for sensorineural hearing loss. Differential diagnoses include multiple sclerosis, acute disseminated encephalomyelitis (ADEM), and CNS vasculitis; however, the combination of retinal and cochlear involvement is more specific for Susac syndrome. The first-line management involves high-dose corticosteroids to control inflammation. Additional immunosuppressive therapies such as IVIG, mycophenolate mofetil, or cyclophosphamide may be required, particularly in severe or refractory cases. In pregnancy, the use of corticosteroids and IVIG is generally acceptable, but other immunosuppressants require careful risk\u2013benefit assessment due to potential teratogenicity and fetal side effects. Close collaboration with maternal\u2013fetal medicine is essential. Option A (Multiple sclerosis) is less likely given the presence of retinal artery occlusions and the triad. Option B (ADEM) typically presents in children and does not feature the characteristic hearing loss and BRAO. Option C (Susac syndrome) correctly identifies the diagnosis based on the clinical triad. Option D (Conversion reaction) is inconsistent with the objective neurological findings and MRI results. \u2022 The classic triad of encephalopathy, BRAO, and sensorineural hearing loss is pathognomonic for Susac syndrome. \u2022 Early recognition and aggressive immunosuppressive therapy can help prevent permanent deficits. \u2022 Susac syndrome is more common in young women. Recent reviews and case series underscore the importance of early immunosuppressive treatment to curb disease progression. Updated guidelines recommend a combination of high-dose steroids and additional immunomodulatory agents based on disease severity, with emerging data supporting individualized treatment regimens.",
    "exam_year": "2018",
    "exam_type": "Promotion",
    "image_url": "page_22.png"
  },
  {
    "question": "Teriflunomide 14 mg compared to interferon:",
    "option_a": "Teriflunomide 14 mg less effective than interferon",
    "option_b": "Teriflunomide 14 mg equal to high dose interferon",
    "option_c": "Teriflunomide 14 mg more effective than high dose interferon.",
    "option_d": "was not provided.",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroimmunology",
    "explanation": "Teriflunomide is an oral disease-modifying therapy (DMT) used in the treatment of relapsing\u2013remitting multiple sclerosis (RRMS). It works by modulating the immune response rather than providing a broad immunosuppression. Teriflunomide selectively and reversibly inhibits the mitochondrial enzyme dihydroorotate dehydrogenase, which is crucial for the de novo synthesis of pyrimidines in rapidly dividing cells like activated lymphocytes. This results in a reduction of T- and B-lymphocyte proliferation, thereby decreasing inflammatory attacks on the central nervous system. Clinically, teriflunomide reduces relapse rates and slows the progression of disability in RRMS. Its oral formulation is an important advantage over injectable therapies, such as interferons, particularly in terms of patient compliance and quality of life. This question relates to treatment comparisons rather than diagnosis. However, treatment selection involves assessing disease activity, patient preferences, and potential contraindications. Differential considerations when choosing a DMT include efficacy, side-effect profiles, route of administration, and individual patient comorbidities. First-line management for RRMS includes several DMT options. Teriflunomide is considered comparable in efficacy to high\u2013dose interferon beta preparations and may be preferred for its oral route. Second-line agents (e.g., fingolimod, dimethyl fumarate) are available for patients with more active disease or who fail first-line therapies. In pregnancy and lactation, teriflunomide is contraindicated due to its known teratogenic potential; a washout procedure is recommended for women who become pregnant while on teriflunomide. In contrast, interferon beta, although used cautiously, is often considered relatively safer if treatment is necessary during pregnancy. Option A stating teriflunomide is less effective than interferon is incorrect. Option B, which suggests that teriflunomide 14 mg is equal in efficacy to high\u2013dose interferon beta, is supported by head-to-head data and network meta-analyses. Option C, claiming it is more effective than high\u2013dose interferon, is not supported by the majority of comparative studies. Option D was not provided. \u2022 Teriflunomide offers an oral alternative to injectable therapies for RRMS with a comparable efficacy profile. \u2022 It acts by inhibiting pyrimidine synthesis, reducing lymphocyte proliferation. \u2022 Its teratogenicity requires strict contraception in women of childbearing potential. Recent clinical trials and meta-analyses have shown that teriflunomide has an efficacy profile equivalent to that of high\u2013dose interferon beta-1a. Current guidelines incorporate teriflunomide as a first-line treatment option for RRMS in appropriately selected patients, with careful counseling regarding its contraindications in pregnancy.",
    "exam_year": "2018",
    "exam_type": "Promotion"
  },
  {
    "question": "NMO, what is correct:",
    "option_a": "10 times more in male than female",
    "option_b": "Monophasic, no relapse",
    "option_c": "NMO lesions shows immunoglobulin and complement deposits in a characteristic vasculo concentric rim and rosette pattern around hyalinized blood vessels.",
    "option_d": "(interpreted here as 'none of the above') is the correct answer.",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Neuroimmunology",
    "explanation": "Neuromyelitis optica (NMO), also known as NMO spectrum disorder, is an autoimmune disorder primarily targeting the optic nerves and spinal cord. It is mediated by antibodies directed against aquaporin-4 (AQP4), a water channel protein on astrocytes. The binding of AQP4 antibodies leads to complement activation and a cascade of inflammatory damage, resulting in astrocytic injury, demyelination, and necrosis in regions where AQP4 is abundant. This immune-mediated process typically results in a relapsing disease course with severe relapses affecting the optic nerves and spinal cord. Clinically, NMO presents with severe episodes of optic neuritis (leading to visual loss) and transverse myelitis (causing motor and sensory deficits). It is predominantly a relapsing disorder with a strong female predilection. Features such as a monophasic course or male predominance would be atypical. Diagnosis is made based on clinical findings, MRI of the brain and spinal cord, and the detection of AQP4 antibodies in serum. Differential diagnoses include multiple sclerosis, acute disseminated encephalomyelitis (ADEM), and other causes of demyelination. Imaging and serological tests help differentiate NMO from these conditions. Acute management typically involves high-dose corticosteroids with or without plasmapheresis if there is an inadequate response. Long-term therapy focuses on immunosuppressants (e.g., azathioprine, mycophenolate mofetil) or newer monoclonal antibodies such as eculizumab, satralizumab, and inebilizumab. In pregnancy, treatment choices require careful risk\u2013benefit analysis; high-dose steroids and IVIG are usually safer for acute attacks, while many long-term immunosuppressants have potential teratogenic risks and should be avoided or used with extreme caution. Option A is incorrect because NMO is significantly more common in females (roughly 9:1 ratio) rather than in males. Option B is incorrect because NMO is typically relapsing rather than monophasic. Option C is incorrect as the described histopathological pattern (immunoglobulin and complement deposits in a vasculo\u2013concentric rim and rosette pattern around hyalinized blood vessels) does not accurately characterize NMO lesions. In reality, NMO lesions are noted for intense deposition of complement and IgG in a perivascular pattern, but not with a distinctive rosette or concentric pattern. Option D (interpreted here as 'none of the above') is the correct answer. \u2022 NMO predominantly affects women and almost always follows a relapsing course. \u2022 The detection of AQP4 antibodies is critical for an accurate diagnosis. \u2022 Histopathology in NMO is characterized by perivascular complement deposition, not the concentric or rosette patterns described in option C. Recent guidelines and clinical trials have refined the diagnostic criteria for NMO, emphasizing the role of AQP4 antibody testing. Advances in therapies, including monoclonal antibodies targeting the complement cascade and B cells, have significantly improved outcomes in NMO, with emerging evidence guiding both acute and maintenance strategies.",
    "exam_year": "2018",
    "exam_type": "Promotion"
  },
  {
    "question": "young lady with progressive insomnia developed psychiatric symptoms, admitted to psychiatry ward, then developed choreiform movement with no improvement by Benzodiazepine, what is the malignancy most likely associated:",
    "option_a": "ovarian teratoma,",
    "option_b": "SCLC",
    "option_c": "Breast Ca.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "This case describes a young woman with an unusual neuropsychiatric presentation \u2013 starting with progressive insomnia and psychiatric abnormalities, followed by movement disorders (choreiform movements) that are refractory to benzodiazepines. This pattern is characteristic of autoimmune encephalitis, particularly anti\u2010NMDA receptor encephalitis, which is classically seen in young females and is often paraneoplastic in origin. In anti\u2010NMDA receptor encephalitis, antibodies are generated (often due to tumor antigens in ovarian teratoma) which cross-react with NMDA receptors in the brain. This immune-mediated attack leads to disturbances in neurotransmission resulting in psychiatric symptoms, movement disorders, seizures, and autonomic instability. Up\u2010to\u2010date research confirms that ovarian teratomas harbor neural tissue that triggers an immune response against these receptors. Patients typically present with a viral\u2010like prodrome followed by rapid emergence of psychiatric symptoms, behavioral changes, and abnormal movements (including chorea or dyskinesia). The lack of response to benzodiazepines further supports that the movement abnormalities are not due to a simple GABAergic deficiency but rather central dysregulation due to antibody-mediated receptor dysfunction. The workup involves MRI of the brain (often may be normal or show subtle changes), EEG (which may show a diffuse slowing or extreme delta brush pattern), and cerebrospinal fluid analysis for anti\u2010NMDA receptor antibodies. Differential diagnoses include primary psychiatric disorders, viral encephalitis (eg, HSV encephalitis), and other autoimmune encephalitides. First\u2010line management includes immunotherapy (high\u2010dose corticosteroids, intravenous immunoglobulin [IVIG] or plasmapheresis) coupled with prompt surgical removal of the ovarian teratoma. If first\u2010line therapy fails, second\u2010line options such as rituximab or cyclophosphamide may be used. In pregnant or lactating patients, corticosteroids are generally safe and IVIG can be considered; tumor resection should be approached carefully with multidisciplinary input. Option A (ovarian teratoma) is correct because it is the most common tumor in young women associated with anti\u2010NMDA receptor encephalitis. Option B (SCLC) and Option C (breast cancer) are more commonly linked with other paraneoplastic syndromes and are not typically seen in this age group with this presentation. Option D is blank and not applicable. 1. In young women presenting with acute psychiatric symptoms and abnormal movements, always consider anti\u2010NMDA receptor encephalitis and evaluate for an ovarian teratoma. 2. Early diagnosis and tumor resection combined with immunotherapy significantly improves outcomes. Recent guidelines and studies emphasize early immunomodulatory therapy and prompt removal of the underlying tumor. The approach to anti\u2010NMDA receptor encephalitis has been refined over the past decade, with improved survival and functional outcomes when treatment is initiated early.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "patient presented with opsoclonus myoclonus, what is the malignancy:",
    "option_a": "Breast",
    "option_b": "Colon.",
    "option_c": "Thyroid",
    "option_d": "Ovary.",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "This case describes a young woman with an unusual neuropsychiatric presentation \u2013 starting with progressive insomnia and psychiatric abnormalities, followed by movement disorders (choreiform movements) that are refractory to benzodiazepines. This pattern is characteristic of autoimmune encephalitis, particularly anti\u2010NMDA receptor encephalitis, which is classically seen in young females and is often paraneoplastic in origin. In anti\u2010NMDA receptor encephalitis, antibodies are generated (often due to tumor antigens in ovarian teratoma) which cross-react with NMDA receptors in the brain. This immune-mediated attack leads to disturbances in neurotransmission resulting in psychiatric symptoms, movement disorders, seizures, and autonomic instability. Up\u2010to\u2010date research confirms that ovarian teratomas harbor neural tissue that triggers an immune response against these receptors. Patients typically present with a viral\u2010like prodrome followed by rapid emergence of psychiatric symptoms, behavioral changes, and abnormal movements (including chorea or dyskinesia). The lack of response to benzodiazepines further supports that the movement abnormalities are not due to a simple GABAergic deficiency but rather central dysregulation due to antibody-mediated receptor dysfunction. The workup involves MRI of the brain (often may be normal or show subtle changes), EEG (which may show a diffuse slowing or extreme delta brush pattern), and cerebrospinal fluid analysis for anti\u2010NMDA receptor antibodies. Differential diagnoses include primary psychiatric disorders, viral encephalitis (eg, HSV encephalitis), and other autoimmune encephalitides. First\u2010line management includes immunotherapy (high\u2010dose corticosteroids, intravenous immunoglobulin [IVIG] or plasmapheresis) coupled with prompt surgical removal of the ovarian teratoma. If first\u2010line therapy fails, second\u2010line options such as rituximab or cyclophosphamide may be used. In pregnant or lactating patients, corticosteroids are generally safe and IVIG can be considered; tumor resection should be approached carefully with multidisciplinary input. Option A (ovarian teratoma) is correct because it is the most common tumor in young women associated with anti\u2010NMDA receptor encephalitis. Option B (SCLC) and Option C (breast cancer) are more commonly linked with other paraneoplastic syndromes and are not typically seen in this age group with this presentation. Option D is blank and not applicable. 1. In young women presenting with acute psychiatric symptoms and abnormal movements, always consider anti\u2010NMDA receptor encephalitis and evaluate for an ovarian teratoma. 2. Early diagnosis and tumor resection combined with immunotherapy significantly improves outcomes. Recent guidelines and studies emphasize early immunomodulatory therapy and prompt removal of the underlying tumor. The approach to anti\u2010NMDA receptor encephalitis has been refined over the past decade, with improved survival and functional outcomes when treatment is initiated early.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "recurrent thunderclap headache, the patient had string of pearls on CTA ESR normal. what is the Dx:",
    "option_a": "Primary CNS angiitis",
    "option_b": "RCVS.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroimmunology",
    "explanation": "This case describes a young woman with an unusual neuropsychiatric presentation \u2013 starting with progressive insomnia and psychiatric abnormalities, followed by movement disorders (choreiform movements) that are refractory to benzodiazepines. This pattern is characteristic of autoimmune encephalitis, particularly anti\u2010NMDA receptor encephalitis, which is classically seen in young females and is often paraneoplastic in origin. In anti\u2010NMDA receptor encephalitis, antibodies are generated (often due to tumor antigens in ovarian teratoma) which cross-react with NMDA receptors in the brain. This immune-mediated attack leads to disturbances in neurotransmission resulting in psychiatric symptoms, movement disorders, seizures, and autonomic instability. Up\u2010to\u2010date research confirms that ovarian teratomas harbor neural tissue that triggers an immune response against these receptors. Patients typically present with a viral\u2010like prodrome followed by rapid emergence of psychiatric symptoms, behavioral changes, and abnormal movements (including chorea or dyskinesia). The lack of response to benzodiazepines further supports that the movement abnormalities are not due to a simple GABAergic deficiency but rather central dysregulation due to antibody-mediated receptor dysfunction. The workup involves MRI of the brain (often may be normal or show subtle changes), EEG (which may show a diffuse slowing or extreme delta brush pattern), and cerebrospinal fluid analysis for anti\u2010NMDA receptor antibodies. Differential diagnoses include primary psychiatric disorders, viral encephalitis (eg, HSV encephalitis), and other autoimmune encephalitides. First\u2010line management includes immunotherapy (high\u2010dose corticosteroids, intravenous immunoglobulin [IVIG] or plasmapheresis) coupled with prompt surgical removal of the ovarian teratoma. If first\u2010line therapy fails, second\u2010line options such as rituximab or cyclophosphamide may be used. In pregnant or lactating patients, corticosteroids are generally safe and IVIG can be considered; tumor resection should be approached carefully with multidisciplinary input. Option A (ovarian teratoma) is correct because it is the most common tumor in young women associated with anti\u2010NMDA receptor encephalitis. Option B (SCLC) and Option C (breast cancer) are more commonly linked with other paraneoplastic syndromes and are not typically seen in this age group with this presentation. Option D is blank and not applicable. 1. In young women presenting with acute psychiatric symptoms and abnormal movements, always consider anti\u2010NMDA receptor encephalitis and evaluate for an ovarian teratoma. 2. Early diagnosis and tumor resection combined with immunotherapy significantly improves outcomes. Recent guidelines and studies emphasize early immunomodulatory therapy and prompt removal of the underlying tumor. The approach to anti\u2010NMDA receptor encephalitis has been refined over the past decade, with improved survival and functional outcomes when treatment is initiated early.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "what is the most of the following scenarios will develop MS:",
    "option_a": "30 years old man with migraine with incidental periventricular lesion & 2 spine lesion with -ve OCB.",
    "option_b": "31 woman with migraine 4 pericollosal & 3 cerebellar plaques but normal spine.",
    "option_c": "52 years old Woman with demyelinating lesion in the brain & OCB in serum.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "This case describes a young woman with an unusual neuropsychiatric presentation \u2013 starting with progressive insomnia and psychiatric abnormalities, followed by movement disorders (choreiform movements) that are refractory to benzodiazepines. This pattern is characteristic of autoimmune encephalitis, particularly anti\u2010NMDA receptor encephalitis, which is classically seen in young females and is often paraneoplastic in origin. In anti\u2010NMDA receptor encephalitis, antibodies are generated (often due to tumor antigens in ovarian teratoma) which cross-react with NMDA receptors in the brain. This immune-mediated attack leads to disturbances in neurotransmission resulting in psychiatric symptoms, movement disorders, seizures, and autonomic instability. Up\u2010to\u2010date research confirms that ovarian teratomas harbor neural tissue that triggers an immune response against these receptors. Patients typically present with a viral\u2010like prodrome followed by rapid emergence of psychiatric symptoms, behavioral changes, and abnormal movements (including chorea or dyskinesia). The lack of response to benzodiazepines further supports that the movement abnormalities are not due to a simple GABAergic deficiency but rather central dysregulation due to antibody-mediated receptor dysfunction. The workup involves MRI of the brain (often may be normal or show subtle changes), EEG (which may show a diffuse slowing or extreme delta brush pattern), and cerebrospinal fluid analysis for anti\u2010NMDA receptor antibodies. Differential diagnoses include primary psychiatric disorders, viral encephalitis (eg, HSV encephalitis), and other autoimmune encephalitides. First\u2010line management includes immunotherapy (high\u2010dose corticosteroids, intravenous immunoglobulin [IVIG] or plasmapheresis) coupled with prompt surgical removal of the ovarian teratoma. If first\u2010line therapy fails, second\u2010line options such as rituximab or cyclophosphamide may be used. In pregnant or lactating patients, corticosteroids are generally safe and IVIG can be considered; tumor resection should be approached carefully with multidisciplinary input. Option A (ovarian teratoma) is correct because it is the most common tumor in young women associated with anti\u2010NMDA receptor encephalitis. Option B (SCLC) and Option C (breast cancer) are more commonly linked with other paraneoplastic syndromes and are not typically seen in this age group with this presentation. Option D is blank and not applicable. 1. In young women presenting with acute psychiatric symptoms and abnormal movements, always consider anti\u2010NMDA receptor encephalitis and evaluate for an ovarian teratoma. 2. Early diagnosis and tumor resection combined with immunotherapy significantly improves outcomes. Recent guidelines and studies emphasize early immunomodulatory therapy and prompt removal of the underlying tumor. The approach to anti\u2010NMDA receptor encephalitis has been refined over the past decade, with improved survival and functional outcomes when treatment is initiated early.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "young female with bilateral optic neuritis, brain MRI showed enhanced contrast in the posterior segment of the optic nerve extending to the optic chiasm, partially improved after pulse steroid after 5 days but VA still 20/200, what is the best next step:",
    "option_a": "send for Aquaporin-4 & wait the result.",
    "option_b": "Start her on prednisolone with taper over 1 month.",
    "option_c": "Urgent Rituximab",
    "option_d": "PLEX",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Neuroimmunology",
    "explanation": "Optic neuritis in a young female, especially when bilateral with chiasmal involvement, raises a high suspicion for neuromyelitis optica spectrum disorder (NMOSD). The condition is characterized by inflammatory demyelination of the optic nerves, and initial management typically involves high\u2010dose IV steroids. NMOSD is mediated by autoantibodies against the aquaporin-4 (AQP4) water channel, resulting in astrocytic injury and secondary demyelination. When an acute attack does not show adequate response to IV steroids\u2014as evidenced by persistently poor visual acuity\u2014this likely reflects a severe inflammatory process where additional removal of circulating autoantibodies can be beneficial. In this patient, the MRI findings (contrast enhancement of the posterior optic nerve extending to the chiasm) together with the clinical picture of bilateral optic neuritis indicate a likely NMOSD-related attack. Lack of full improvement after 5 days of pulse steroids (visual acuity still 20/200) calls for escalation of therapy. In cases of optic neuritis, differential diagnoses include multiple sclerosis (often unilateral and with a different MRI distribution) and ischemic optic neuropathy. The diagnostic workup typically involves neuroimaging (MRI) and laboratory testing including AQP4 antibody titers, although waiting for results should not delay urgent treatment in a worsening clinical scenario. First-line management for an acute NMOSD attack is high-dose IV methylprednisolone. If there is an inadequate response as seen here, guidelines recommend escalation to plasma exchange (PLEX) to remove pathogenic autoantibodies. Long-term management may involve immunosuppressive agents like rituximab. In pregnancy and lactation, steroids are generally considered safe; plasmapheresis can also be performed with appropriate monitoring, although each patient\u2019s risks and benefits must be individually assessed. Option A: Sending for AQP4 antibody testing is useful for diagnostic confirmation but waiting for results may delay necessary urgent therapy. Option B: Starting an oral prednisolone taper may not provide the rapid immunomodulation required in a steroid-refractory attack. Option C: Rituximab is primarily used for long-term immunosuppression rather than for immediate rescue therapy. Option D: PLEX is the recommended next step in steroid-refractory cases, making this the best answer. 1. Bilateral optic neuritis with chiasmal involvement is a red flag for NMOSD rather than classic MS. 2. Inadequate response to high-dose steroids necessitates rapid escalation therapy. 3. Early initiation of PLEX in refractory attacks can improve long-term visual outcomes. Recent studies and updated clinical guidelines have demonstrated the efficacy of PLEX in acute NMOSD attacks that do not adequately respond to steroids, underscoring its role as a vital rescue therapy in these patients.",
    "exam_year": "2019",
    "exam_type": "Promotion",
    "image_url": "page_3.png"
  },
  {
    "question": "patient losing the clutch, has Lhermitte sign, ataxia worse with night, blood film is abnormal, Dx:",
    "option_a": "Subacute combined degeneration.",
    "option_b": "Syphilis.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Subacute combined degeneration (SCD) is a neurological disorder resulting from vitamin B12 deficiency. It primarily affects the dorsal columns and lateral corticospinal tracts and is typically associated with hematologic findings of macrocytic anemia. Vitamin B12 is essential for myelin formation and neuronal function. Deficiency leads to impaired myelin synthesis, resulting in demyelination of the posterior columns (responsible for proprioception and vibration sense) and lateral corticospinal tracts (affecting motor control). The presence of an abnormal blood film further supports the diagnosis, as macrocytic changes are common. The presentation with Lhermitte's sign (an electric shock\u2010like sensation on neck flexion), ataxia (which may be more evident in low light or at night), and an abnormal blood smear (indicative of macrocytosis) aligns well with SCD. This helps differentiate it from other conditions that might present with similar neurological signs. Differential diagnoses include multiple sclerosis (which typically does not present with macrocytic anemia), and neurosyphilis (tabes dorsalis) which presents with ataxia and sensory disturbances but lacks the hematologic abnormalities. Confirmation is achieved by measuring serum vitamin B12 levels, methylmalonic acid, and homocysteine. The first-line treatment is vitamin B12 supplementation (usually via intramuscular injections or high-dose oral therapy). Early treatment is crucial to prevent irreversible neurological damage. In pregnant or lactating patients, vitamin B12 supplementation is safe and recommended, with dosing adjusted based on severity and clinical response. Option A (Subacute combined degeneration) correctly correlates with the clinical findings and the abnormal blood film. Option B (Syphilis) is less likely given the hematologic evidence, as syphilis does not typically cause macrocytic anemia or the specific blood film abnormalities seen in B12 deficiency. 1. Always check vitamin B12 levels in patients with neurological symptoms and macrocytic anemia. 2. Lhermitte's sign is not specific to multiple sclerosis and can be seen in B12 deficiency. 3. Early detection and treatment of B12 deficiency can lead to significant reversal of neurological deficits. Updated clinical guidelines emphasize early screening for vitamin B12 deficiency in patients with neurological symptoms, as prompt treatment is crucial in preventing permanent deficits. Recent reviews reiterate the reversibility of SCD if intervention occurs in a timely manner.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "female patient, with CNS manifestation, she has hearing loss, she has retinal artery occlusion:",
    "option_a": "CADASIL.",
    "option_b": "Susac syndrome.",
    "option_c": "MS",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroimmunology",
    "explanation": "Susac syndrome is a rare autoimmune microangiopathy characterized by a clinical triad: encephalopathy, branch retinal artery occlusions, and sensorineural hearing loss. It primarily affects small blood vessels in the brain, retina, and inner ear. The syndrome is thought to result from an immune-mediated endotheliopathy leading to microvascular occlusions. Damage to the endothelium causes ischemic injury in the brain, retina, and cochlea, which accounts for the constellation of neurological, visual, and auditory symptoms. In a female patient presenting with CNS manifestations, hearing loss, and retinal artery occlusion, the clinical triad points directly to Susac syndrome. This differentiates it from other conditions like multiple sclerosis or CADASIL, which do not typically present with branch retinal artery occlusions and hearing loss. Differentials include CADASIL (which is a genetic small vessel disease typically associated with migraines and subcortical infarcts) and multiple sclerosis (which lacks the characteristic retinal and auditory findings). Fluorescein angiography of the retina can help confirm branch retinal artery occlusions. Brain MRI and audiometric testing further support the diagnosis. First-line treatment generally involves high-dose corticosteroids, often in conjunction with other immunosuppressive therapies such as IVIG or cyclophosphamide. In pregnant or lactating patients, treatment decisions must carefully balance maternal benefit against potential fetal risks, often favoring corticosteroids with close monitoring. Option A (CADASIL) typically presents with migraine and subcortical ischemic events but does not include the triad seen in Susac syndrome. Option B (Susac syndrome) is correct as it matches the clinical presentation. Option C (MS) is less likely given the presence of branch retinal artery occlusion and sensorineural hearing loss, which are atypical for MS. 1. The classic triad of encephalopathy, branch retinal artery occlusion, and sensorineural hearing loss is pathognomonic for Susac syndrome. 2. Early recognition and aggressive treatment are essential to prevent permanent sensory deficits. 3. Fluorescein angiography is a valuable diagnostic tool in suspected cases. Recent research underscores the importance of early immunosuppressive therapy in Susac syndrome to limit irreversible microvascular damage. Emerging studies continue to refine treatment protocols to balance efficacy and safety, particularly in special populations such as pregnant women.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "patient with MS has spasticity & difficult gait, what is the medication improved his gait:",
    "option_a": "fingolimod.",
    "option_b": "Interferon",
    "option_c": "Dalfampridine",
    "option_d": "Ocrelizumab",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuroimmunology",
    "explanation": "Multiple sclerosis (MS) is a demyelinating disease that can lead to various neurological symptoms, including spasticity and gait difficulties. Dalfampridine is a symptomatic treatment specifically approved to improve walking speed in patients with MS. Dalfampridine (4-aminopyridine) acts as a potassium channel blocker, which helps to ameliorate conduction in demyelinated nerve fibers by prolonging action potentials. This pharmacologic enhancement of nerve conduction is responsible for improved motor function and gait in patients with MS. Patients with MS often experience gait disturbances and spasticity as a consequence of demyelination in motor pathways. Dalfampridine has been shown to improve walking speed and overall mobility, thereby enhancing quality of life for these patients. The diagnosis of MS is established based on clinical criteria (McDonald criteria) and supported by MRI findings. Alternative symptomatic therapies, such as spasticity management with baclofen or tizanidine, may be used for spasticity but do not directly target gait improvement. First-line management of gait impairment in MS includes the use of dalfampridine as it is FDA-approved for this indication. While disease-modifying drugs (such as fingolimod, interferon, and ocrelizumab) are crucial for long-term management of MS, they are not primarily indicated for acute symptomatic improvement in gait. In pregnant or lactating women, the use of dalfampridine should be carefully considered by weighing potential benefits against the limited safety data; alternative supportive therapies and physical rehabilitation may be prioritized. Option A (Fingolimod) and Option B (Interferon) are disease-modifying therapies and do not provide direct symptomatic relief for gait disturbances. Option D (Ocrelizumab) is also a disease-modifying monoclonal antibody used in MS. Option C (Dalfampridine) is correct because it is specifically indicated to improve walking speed in patients with MS. 1. Dalfampridine is the only agent specifically approved to improve walking speed in MS. 2. It should be avoided in patients with a history of seizures due to its mechanism of action. 3. Symptomatic treatment with dalfampridine can be combined with physical therapy for optimal gait improvement. Recent clinical trials and updated guidelines reaffirm dalfampridine's efficacy in enhancing gait in MS patients. Ongoing research continues to evaluate its long-term benefits and safety profile, particularly in subpopulations such as those with concomitant seizure risk or during pregnancy.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  }
]